Glenmark – Recall of zonisamide capsules

- On April 25, 2022, Glenmark announced a consumer-level recall of several lots of zonisamide capsules due to gaps in the microbiology quality control system or due to lack of stability data.

Product Description	NDC#	Lot# (Expiration Date)
Zonisamide 100 mg capsules	68462-130-01	29200053 (04/30/2023); 29200015 (03/31/2023); 29200016 (03/31/2023); 29200030 (05/31/2023); 29200031 (05/31/2023); 29200032 (05/31/2023); 29200033 (06/30/2023); 29200037 (06/30/2023); 29200038 (06/30/2023); 29200039 (07/31/2023); 29200041 (07/31/2023); 29200042 (07/31/2023); 29200048 (08/31/2023); 29200014 (02/28/2023); 29200050 (08/31/2023); 29200072 (11/30/2023); 29200073 (11/30/2023); 29200074 (11/30/2023); 29200075 (11/30/2023); 29200076 (11/30/2023); 29200049 (08/31/2023)
	68462-130-05	29200014 (02/28/2023); 29200015 (03/31/2023); 29200016 (03/31/2023); 29200054 (04/30/2023)
Zonisamide 25 mg capsules	68462-128-01	29200052 04/30/2023
Zonisamide 50 mg capsules	68462-129-01	29200064 (05/31/2023); 29190043 (05/31/2022); 29190044 (05/31/2022); 29190045 (05/31/2022)

- Zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- Patients should contact their physician or health care provider if they have experienced any problems that may be related to taking or using the recalled zonisamide.

Continued . . .

- Contact Qualanex by phone at **1-888-504-2012** or by email at **recall@qualanex.com** for return information and for more information about the recall.

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.

© 2022 Optum, Inc. All rights reserved. ORX6547968A-TEMPLATE_220208